Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients

Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients

Abstract A definitive diagnosis of Alzheimer’s disease (AD), even in the presence of co-morbid neuropathology (occurring in > 50% of AD cases), is a significant unmet medical need that has obstructed the discovery of effective AD therapeutics. An AD-biomarker, the Morphometric Imaging (MI) assay...

Full description

Bibliographic Details
Main Authors: Florin V. Chirila, Guang Xu, Dan Fontaine, Grant Kern, Tapan K. Khan, Jason Brandt, Yoshihiro Konishi, Gerhard Nebe-von-Caron, Charles L. White, Daniel L. Alkon
Format: Article
Language:English
Published: Nature Portfolio 2022-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-21796-y

Internet

https://doi.org/10.1038/s41598-022-21796-y

Similar Items